Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Pamufetinib (TAS-115), an oral multikinase inhibitor, failed to slow FVC decline compared with continued nintedanib or pirfenidone in a phase 2b trial of patients with progressive 

chronic fibrosing interstitial lung disease (CF-ILD).

“The FVC decline in the pamufetinib 100 mg group was suppressed until week 10, which was consistent with the previous phase 2a study,” wrote investigator Ryo Okuda, from Kanagawa Cardiovascular and Respiratory Center in Japan, and colleagues.

 “However, after week 16, the rate of FVC decline was reversed, resulting in an FVC that was lower in the pamufetinib 100 mg group than the control group.”

No therapy is currently recommended for CF-ILD with disease progression despite treatment with nintedanib or pirfenidone. The earlier phase 2a single-arm study of pamufetinib suggested a delay in disease progression among patients with FVC decline on standard antifibrotic therapy, using intrapatient slope change as a surrogate endpoint.² This phase 2b study tested whether the signal would translate into a dose-dependent benefit when pamufetinib replaced standard antifibrotic therapy outright.

Pamufetinib Efficacy in the Phase 2b Chronic Fibrosing ILD Trial

This double-blind, multicenter, active-controlled phase 2b trial enrolled patients at 41 sites in Japan between October 2021 and June 2024.¹ Eligible patients had CF-ILD with a progressive phenotype, defined as a relative %FVC decline of ≥ 5% per year despite nintedanib or pirfenidone, and an %FVC of ≥ 50%. Patients were randomized 1:1:1 to pamufetinib 100 mg, pamufetinib 50 mg, or control therapy consisting of continued nintedanib or pirfenidone, using a double-dummy design to preserve blinding across the differing dosage forms.

Pamufetinib was administered on a 5-day-on/2-day-off oral schedule for 26 weeks. Of 243 patients randomized and treated, 71.0% had IPF, and mean %FVC was approximately 74% across the 3 arms.

The primary endpoint, 26-week rate of decline in FVC, was -157.8 mL (95% CI, -208.8 to -106.9) with pamufetinib 100 mg, -96.0 mL (95% CI, -145.4 to -46.6) with pamufetinib 50 mg, and -63.6 mL (95% CI, -111.8 to -15.5) with control therapy. No dose-response relationship was observed, and the 100 mg arm showed a numerically greater decline than control. Investigators noted the 100 mg arm maintained early suppression of FVC decline through week 10 before the effect reversed between weeks 16 and 26.

Pamufetinib Safety Profile and Secondary Endpoints in CF-ILD

Pamufetinib 50 mg and 100 mg failed to slow 26-week FVC decline versus continued nintedanib or pirfenidone in 243 patients with progressive CF-ILD (-96.0 mL and -157.8 mL vs -63.6 mL with control).

No dose-response relationship was observed, and the 100 mg dose showed numerically greater FVC decline and more acute exacerbations than control.

Switching from standard antifibrotic monotherapy to pamufetinib provided no benefit, leaving nintedanib and pirfenidone the only approved options for CF-ILD.

Absolute change in %DLco from baseline at 26 weeks was -5.2% with pamufetinib 100 mg, -3.4% with pamufetinib 50 mg, and -2.6% with control therapy.¹ Acute exacerbation occurred in 12.8% (10/78) of the pamufetinib 100 mg group, 9.6% (8/83) of the pamufetinib 50 mg group, and 3.8% (3/80) of the control group by week 26. Death occurred in 3.8%, 6.0%, and 2.5% of patients, respectively, though the 26-week trial was not designed to detect survival differences.

Rash was the most frequent adverse event in both pamufetinib arms, reported in 29.1% of the 100 mg group and 14.3% of the 50 mg group versus 10.0% of the control group. Most cases were mild to moderate in severity.

Adverse events coded as ILD, encompassing both acute exacerbations and newly diagnosed disease, occurred in 10.1% of the 100 mg group, 9.5% of the 50 mg group, and 3.8% of the control group. The study reported serious adverse events in 27.8%, 20.2%, and 15.0% of patients across the same groups. Treatment discontinuation occurred in 12.7% and 11.9% of the pamufetinib 100 mg and 50 mg groups, respectively, compared with no discontinuations in the control group.

Investigators attributed the unfavorable FVC trajectory partly to pamufetinib's off-target inhibition of MET, AXL, and Src alongside its intended PDGFR, VEGFR, and CSF1R targets, since MET signaling supports alveolar epithelial repair after lung injury.³ Subgroup analyses stratified by IPF status and prior antifibrotic treatment showed results consistent with the overall population, with no benefit favoring pamufetinib.¹

The findings indicate no advantage to switching from standard antifibrotic monotherapy to pamufetinib in patients progressing despite treatment, leaving nintedanib and pirfenidone the only approved options for CF-ILD.

Okuda R, Nishioka Y, Kondoh Y, et al. Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial. 

Nishioka Y, Homma S, Ogura T, et al. Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis. 

Articles

Pamufetinib (TAS-115), an oral multikinase inhibitor, did not improve physiologic outcomes when substituted for nintedanib or pirfenidone in progressive chronic fibrosing ILD. In a double-blind, active-controlled phase 2b Japanese study, FVC decline at 26 weeks was numerically worse with pamufetinib 100 mg and not dose-responsive versus control therapy. Early FVC suppression through week 10 in the 100 mg arm reversed after week 16. Safety signals included higher rash rates, more acute exacerbations, and greater discontinuations.

Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Pamufetinib Fails to Slow FVC Decline in Progressive Fibrosing ILD

Part 2 of the phase 3 ABTECT maintenance trial found that obefazimod sustained clinical remission through week 44 in

patients, including those who had not initially responded to induction therapy. The results build on positive Part 1 data and add to a growing safety database ahead of the company's planned 

"These results that we'll probably be talking about today are really building upon very impressive induction data, where we saw placebo-adjusted treatment differences for the primary endpoint of clinical remission, which was quite substantial," Remo Panaccione, MD, professor of medicine and director of the IBD Clinic at the University of Calgary, said in an interview with HCPLive.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD

How Large Was the ABTECT Maintenance Population?

Panaccione noted the onset of benefit was rapid, "with separation from placebo as early as one week for symptomatic response and week two for symptomatic remission." Part 1 of the maintenance study enrolled 580 patients who had responded to induction and entered the randomized, placebo-controlled maintenance phase, while Part 2 added 633 patients who had either not responded during induction or lost response during maintenance.

"This study also included a substantial portion of patients who were difficult to treat," Panaccione said. "In particular, it enrolled the largest cohort of patients with an inadequate response to a JAK inhibitor that we've ever studied in phase three clinical trials." He noted JAK inhibitor exposure typically signals later-line therapy, where patients tend to respond less robustly than treatment-naive patients or those exposed only to monoclonal antibodies.

Both the 25 mg and 50 mg doses met the primary endpoint of clinical remission at week 44, with remission rates around 51% compared to 10% with placebo. "This 40% difference, which is the largest placebo-adjusted difference that we've seen in a phase three trial, part of that may have been due to the fact that the placebo rate was quite low, and that speaks usually to the difficult-to-treat patient population," Panaccione said. Among initial non-responders continued on 50 mg, approximately 37% achieved remission and >60% achieved response; among those who relapsed on 25 mg and were escalated to 50 mg, remission was recaptured in approximately 56%.

What Did Endoscopic Remission Rates Show?

For Panaccione, the endoscopic data carried particular weight. "To get into the trial, the patients needed a Mayo endoscopy score of either two or three, signaling moderate to severe endoscopic disease. To achieve endoscopic remission, you needed to go all the way from that down to an endoscopic score of zero," he said. "This is important because this is a highly objective measure of drug efficacy."

Endoscopic remission was achieved in 41.5% of patients on 25 mg and 47.7% on 50 mg, compared to 10% with placebo. "These are amongst the highest endoscopic remission rates that we've seen, and this strong endoscopic remission data really signifies or signals the potential of this drug in moderate to severe ulcerative colitis," Panaccione said. Both doses also met key secondary endpoints, including endoscopic improvement, histologic-endoscopic mucosal improvement, and steroid-free remission, with no concerning safety signals through 44 weeks.

Is Obefazimod's Safety Profile Holding Up With Longer Exposure?

Addressing the drug's safety profile, Panaccione cautioned against over-reading early signals. "When the induction data was first released publicly, there were a few malignancies in the 50 mg dose, and I think that was a little bit misinterpreted," he said. "When we're interpreting rare safety events such as malignancy, it's important not to focus solely on the raw numbers... simple case counts can be really misleading, particularly when the amount of treatment exposure differs amongst groups."

He explained that the 50 mg group had both the greatest cumulative exposure and the most treatment-refractory patients, which would naturally be expected to produce more events. "The important thing is to look at exposure-adjusted incidence rates, and that's a more appropriate way to look at safety in general," Panaccione said.

Across the phase 2 and phase 3 programs, exposure totaled >1,700 patient-years. Rates of non-melanocytic skin cancer were consistent with published malignancy rates in UC, Panaccione said, noting that a prostate cancer and a breast cancer observed in the 50 mg group were not rare cancers and occurred in patients where they would be expected. "Certainly, the available data doesn't suggest a dose-dependent malignancy signal with obefazimod," he said. With phase 2 data now extending beyond four years, Panaccione characterized the overall benefit-risk profile as favorable.

Editors' note: Panaccione has relevant disclosures with Abbott, AbbVie, Abivax, Alimentiv, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Ferring, Galapagos, Gilead Sciences, Janssen, Merck, Novartis, Pfizer, Takeda, and others.

Abivax announces landmark Phase 3 ABTECT maintenance trial results evaluating obefazimod in moderately to severely active ulcerative colitis. News release. Abivax. June 1, 2026. Accessed August 19, 2026. 

https://www.globenewswire.com/news-release/2026/06/01/3304711/0/en/abivax-announces-landmark-phase-3-abtect-maintenance-trial-results-evaluating-obefazimod-in-moderately-to-severely-active-ulcerative-colitis.html

Abivax reports positive ABTECT maintenance Part 2 results for obefazimod, demonstrating meaningful clinical benefit in refractory ulcerative colitis patients and strengthening the Phase 3 maintenance safety database. News release. Abivax. June 29, 2026. Accessed August 19, 2026. 

https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results/

Videos

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Melinda Gooderham, MD, is a dermatologist and the medical director at the SKiN Centre for Dermatology.

Upadacitinib met its primary endpoint in both UP-AA trials, with 45.2% (15 mg) and 55.0% (30 mg) of patients reaching 80%+ scalp hair regrowth by Week 24, versus just 1.5%-3.4% on placebo.

Beyond the scalp, roughly 40%-60% of patients saw meaningful eyebrow and eyelash regrowth, addressing losses that are especially hard to camouflage.

No new safety signals emerged, and the drug showed the most favorable risk-benefit ratio in adolescents, the group most affected psychosocially by alopecia areata.

The European Commission approved upadacitinib for adolescents and adults 12 years and older with 

 in July 2026, while a decision on AbbVie's supplemental new drug application remains pending at the FDA.² The application draws on the phase 3 UP-AA1 and UP-AA2 trials, which also captured hair regrowth beyond the scalp and a consistent safety profile through Week 24.¹

At baseline, about two-thirds of patients had meaningful eyebrow loss and half had meaningful eyelash loss, deficits difficult to camouflage and carrying a functional role in protecting the eyes.¹ By Week 24, meaningful eyebrow regrowth occurred in about 40% of patients on the 15-mg dose and 60% on the 30-mg dose, with a similar pattern for eyelash regrowth.¹

Safety findings showed no new signals across the trials, consistent with upadacitinib's established profile in rheumatoid arthritis, inflammatory bowel disease, and atopic dermatitis.¹ For clinicians, this combination of efficacy and a familiar safety profile offers a well-characterized option for patients who have often exhausted other therapies.

Safety data across the age spectrum studied showed the most favorable risk-benefit ratio in adolescents, a population in which alopecia areata carries substantial psychosocial impact.¹ Many patients with severe alopecia areata have discontinued treatment altogether after limited success with other options, underscoring demand for therapies with higher regrowth rates.

Melinda Gooderham, MD, FRCPC, is a dermatologist and medical director at SKiN Centre for Dermatology and an assistant professor at Queen's University. In the following 

 Q&A interview, Gooderham discusses eyebrow and eyelash outcomes, the safety profile, and where upadacitinib fits among treatment options for severe alopecia areata.

: Beyond scalp regrowth, the study showed improvement in eyebrow, eyelash hair, and quality-of-life measures. Why are these endpoints significant?

 Those are important endpoints as well, because at baseline, about two-thirds of patients had meaningful eyebrow loss and half of patients had meaningful eyelash loss, and that's difficult for patients because it's hard to hide. You can hide scalp hair loss by wearing a wig, but eyebrows need to be tattooed on, and eyelashes are also hard to hide.

There's functionality involved too: eyebrows keep sweat from running into your eyes, and eyelashes keep dirt from getting into your eyes, so it's not only a cosmetic problem but a functional one. At Week 24, eyebrow growth was seen in about 40% of patients on the 15 mg dose and about 60% of patients on the 30 mg dose, and we saw the same pattern with the eyelashes. They had meaningful growth in their eyebrows and eyelashes, so the results are both functionally and cosmetically significant.

: There were no new safety signals. How does this shape your confidence in upadacitinib for this population, including adolescents?

I have high confidence because we haven't yet seen levels of regrowth like this with any other drugs, and that's been exciting. This is a cross-trial comparison to the other studies, not head-to-head, but we saw about 35% SALT20 scores with some of the other drugs, not 45% to 55%, so these are really great levels of improvement.

We're familiar with upadacitinib from treating patients with atopic dermatitis, and we have loads of safety data from other indications, such as rheumatoid arthritis, inflammatory bowel disease, and atopic dermatitis, so we're comfortable with the safety profile and know how to use this drug. Paired with the high levels of response, I think this is really going to raise the bar for this population of patients.

: Looking at the bigger picture, where does this data position upadacitinib among treatment options for severe alopecia areata?

 I hope clinicians see this raises the bar, and we're able to do better for our patients by giving them a well-established medication with really good results. Half of our patients get to SALT20, a third to half get to SALT90 depending on the dose used, and even 1 out of 5 patients get complete full regrowth. I hope clinicians will see severe AA can be treated now. There are many patients out there who have given up on treatment, so knowing severe AA is treatable, and knowing it treats not only the scalp but also the eyebrows, the eyelashes, and the beard in men looking to grow one, is meaningful.

It's safe in adolescence, and when you look at the safety data for upadacitinib across the whole age spectrum, we see the best risk-benefit ratio in that adolescent group. When alopecia areata develops in adolescence, it can have the greatest psychosocial impact, so it's really important to see the efficacy, the safety, and the great risk-benefit ratio in the adolescent age group.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Gooderham has reported non-financial support from Takeda in addition to personal fees from AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Meiji, Dermavant, Moonlake, Nektar, Nimbus, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Tarsus, Takeda, UCB, Union, Ventyx, and Apogee.

Mostaghimi A, et al. Upadacitinib for severe alopecia areata in adults and adolescents: two phase 3 UP-AA randomized clinical trials. 

. Published online August 12, 2026. doi:10.1001/jamadermatol.2026.2853.

Bosslett M. EU approves upadacitinib for severe alopecia as US review remains pending. 

. Published August 6, 2026. Accessed August 20, 2026. 

https://www.dermatologytimes.com/view/eu-approves-upadacitinib-for-severe-alopecia-as-us-review-remains-pending

Upadacitinib has been approved in the EU for severe alopecia areata in patients aged ≥12 years, with US FDA review still pending, supported by phase 3 UP-AA1/UP-AA2 data through Week 24. Beyond scalp endpoints, eyebrow and eyelash regrowth addressed common, hard-to-camouflage deficits with functional implications. Meaningful eyebrow regrowth occurred in ~40% (15 mg) and ~60% (30 mg), with similar eyelash outcomes. Safety was consistent with the established profile across other immune-mediated diseases, with particularly favorable adolescent risk–benefit.

This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.

Alopecia

Q&A: Upadacitinib Drives Eyebrow, Eyelash Regrowth with Consistent Safety

Andrew Mastro, MS, PA-C, is a board-certified PA and guest lecturer at both Rush University and Northwestern University. 

In this episode, ‘The Future of Plaque Psoriasis Treatment Over the Next 3 to 5 Years,’ the panelists, both practicing in dermatology, explore what lies ahead for the field.

The Future of Plaque Psoriasis Treatment Over the Next 3 to 5 Years

Andrew Mastro, MS, PA-C, closes out this stretch of the conversation by asking Alexa Hetzel, MS, PA-C, to look three to five years ahead and describe how she expects the plaque psoriasis treatment paradigm to evolve. Hetzel says her hope is straightforward: that every patient who needs advanced systemic or biologic therapy is actually on it, an outcome she believes depends on continued clinician education translating into better patient education down the line.

She notes there is still meaningful activity in the pipeline, including potential oral options and biologics dosed as infrequently as every six months or once a year, depending on how efficacy data develops. Hetzel frames that pipeline as good news for patients who will be managing this disease for life, since more mechanisms and dosing formats give clinicians a more customizable approach for each individual. She also points out that she and Mastro, despite both treating psoriasis extensively, do not necessarily follow identical treatment algorithms, which she sees as evidence that having a range of options benefits the field rather than complicating it.

Mastro builds on that point, describing the growing menu of therapies as reason for clinicians to stay current on the literature and maintain fluency across mechanisms, since patients increasingly arrive at appointments having already researched their options themselves. He describes the field as a constantly evolving array of choices that requires ongoing effort from providers to track, comparing it to a smorgasbord that keeps expanding rather than settling into a fixed set of options.

Hetzel agrees and adds a final piece to the future outlook: access. Even as the range of effective therapies grows, she says ensuring patients can actually obtain the medicine they need remains the last, and arguably most persistent, barrier to translating better treatment options into better outcomes. A wider menu of oral and injectable choices does little for a patient who cannot get in the door or secure coverage for the agent that fits them best, which is why she views access, alongside continued clinician and patient education, as the piece the field still needs to solve as the treatment landscape keeps expanding over the next several years.

In the next episode, ‘Access Gaps and Treatment Failure in Plaque Psoriasis Care,’ the panelists address lingering barriers to access and how to distinguish primary from secondary treatment failure.

Andrew Mastro, MS, PA-C, closes out this stretch of the conversation by asking Alexa Hetzel, MS, PA-C, to look three to five years ahead and describe how she expects the plaque psoriasis treatment paradigm to evolve.

This episode, titled ‘Positioning Icotrokinra as First-Line Therapy for Plaque Psoriasis,’ features panelists making the case for first-line use.

Positioning Icotrokinra as First-Line Therapy for Plaque Psoriasis

Andrew Mastro, MS, PA-C, widens the lens and asks Alexa Hetzel, MS, PA-C, where icotrokinra sits within the broader plaque psoriasis landscape, including whether route of administration itself shapes patient preference. Hetzel says icotrokinra has become her first-line choice over other oral therapies in the roughly 12 weeks she has had access to it. She adds that it also holds value even before biologic therapy is considered, since patients in the clinical trials who had previously tried and either failed or lost insurance coverage for a biologic still responded to the oral peptide. Because no single therapy works for every patient, Hetzel says the goal is not a one-size-fits-all answer but a wider set of options that increases the odds any given patient finds one that works long term.

Hetzel also flags a messaging shift she considers important: earlier oral agents were sometimes positioned as a stepping stone toward eventual biologic therapy, but she does not see icotrokinra the same way, pointing to sustained response through 52 weeks as evidence it can serve as a durable, standalone choice rather than a bridge.

Asked to name the single most practice-changing takeaway from the discussion, Hetzel offers three. First, icotrokinra works through a mechanism, IL-23 receptor inhibition, that clinicians are already comfortable with, lowering the barrier to adoption. Second, she urges clinicians to use updated guidelines not just to guide their own prescribing but to advocate for patients facing insurance denials or delays in accessing systemic therapy. Third, and somewhat unprompted, she raises the simple importance of patients answering the phone, noting that even the most effective therapy cannot help a patient who does not follow through on next steps. Hetzel likens hesitant patients to an online shopper who saves an item for later rather than checking out, and stresses that clinicians have to actively walk patients through that final step rather than assuming they will follow up on their own.

In the next episode, ‘The Future of Plaque Psoriasis Treatment Over the Next 3 to 5 Years,’ Mastro and Hetzel look ahead at how the treatment paradigm may continue to evolve.

Andrew Mastro, MS, PA-C, widens the lens and asks Alexa Hetzel, MS, PA-C, where icotrokinra sits within the broader plaque psoriasis landscape, including whether route of administration itself shapes patient preference.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

PAH specialists discuss upfront combination therapy and the disconnect between guidelines and community practice.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

PAH in Community Practice: Algorithms and Access

Genetic variants tied to CAR T toxicity and expansion could guide how researchers screen healthy donors for allogeneic CAR T products.

Hematology

Selecting Donor T Cells for CAR T Therapy, With Mark B. Leick, MD

This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.

Q&A: Upadacitinib Meets Primary Endpoint in Severe Alopecia Areata Trials

Nathaniel Lebowitz, MD, is an attending cardiologist at the Hackensack University School of Medicine and an assistant professor of internal medicine at the Hackensack Meridian School of Medicine.

Lp(a) is one of the biggest contributors to cardiovascular disease, but recent studies have shown that awareness of and testing for the condition is subpar nationwide.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

AHA Publishes Results of Nationwide Initiative for Lp(a) Education and Awareness

Deupirfenidone 825 mg reduced 26-week FVC decline by 91.0 mL versus placebo in the phase 2b ELEVATE-IPF trial in idiopathic pulmonary fibrosis.

Deupirfenidone Slows FVC Decline in Phase 2b IPF Trial

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Left Atrial Strain Indicates Worse ATTR-CM Prognosis, but Attenuable With Vutrisiran

The generic nasal spray is bioequivalent to Haleon's Flonase, indicated for nasal symptoms of allergic rhinitis.

FDA News

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

FDA Approves Glenmark’s Generic Fluticasone Propionate Nasal Spray

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Lower TMS Intensity Correlates With Greater Depression Improvement

The Fast Track designation adds to LTI-03's prior Orphan Drug status as Rein Therapeutics advances the Phase 2 RENEW trial in IPF.

FDA Fast Tracks LTI-03 for Idiopathic Pulmonary Fibrosis

In this interview, Melinda Gooderham, MD, MSc, touches on eyebrow and eyelash regrowth data and safety findings for upadacitinib in severe alopecia areata.

Latest News

Pamufetinib Fails to Slow FVC Decline in Progressive Fibrosing ILD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD

Q&A: Upadacitinib Drives Eyebrow, Eyelash Regrowth with Consistent Safety

The Future of Plaque Psoriasis Treatment Over the Next 3 to 5 Years

Positioning Icotrokinra as First-Line Therapy for Plaque Psoriasis